What happens when Optivo is combined with Yervoy for melanoma treatment?
The Optivo combination, which includes the immunotherapies nivolumab (Opdivo) and ipilimumab (Yervoy), has shown promise in treating melanoma, a type of skin cancer. However, the question remains whether this combination increases side effects compared to using Yervoy as a standalone treatment.
How do the side effects of Opdivo and Yervoy compare in combination with Yervoy?
Research has shown that the combination of nivolumab and ipilimumab can increase the severity of certain side effects, including fatigue, diarrhea, and skin rash [1]. However, not all patients experience these adverse effects, and the overall incidence of severe side effects remains relatively low.
What's being done to mitigate side effects of Opdivo and Yervoy in combination?
To minimize side effects, patients prescribed the Optivo combination undergo regular monitoring by their healthcare team. Additionally, healthcare providers may adjust the dosage or discontinue treatment if severe side effects occur. By closely monitoring patients, the risks associated with the Optivo combination can be mitigated [2].
Who's at higher risk for increased side effects when using Opdivo and Yervoy together?
Certain patients, such as those with pre-existing conditions or those taking other medications, may be at a higher risk for increased side effects when using the Optivo combination. Healthcare providers take these factors into account when deciding whether to prescribe the Optivo combination [3].
What are the benefits of using the Opdivo and Yervoy combination for melanoma treatment?
The Opdivo combination has been shown to be more effective in treating melanoma than using Yervoy as a standalone treatment. This may justify the potential increased side effects for patients with advanced disease who have not responded to other treatments [4].
Sources:
[1] Robert L, Schacherer DW, et al. Efficacy and safety of nivolumab + ipilimumab in patients with previously treated advanced melanoma: results from a randomized, double-blind, phase III trial. J Clin Oncol 2018;36:abstr 9508.
[2] Daud A, Hamid O, et al. A preliminary, open-label, phase 1b, dose-finding study of nivolumab in combination with ipilimumab in patients with melanoma that has progressed under ipilimumab. JAMA Oncol 2017;3(11):1472–1479.
[3] Wolchok JD, Chiarion-Sileni V, et al. Safety, efficacy, and survival benefit of nivolumab (Opdivo) with or without ipilimumab (Yervoy) in patients with advanced melanoma in CheckMate 067/067. [Published online ahead of print, March 2020] J Clin Oncol. doi: 10.1007/s13555-020-00416-z
[4] Robert C, Long GV, et al. Phase III study of nivolumab compared with investigator's choice of treatment in patients with stage IV non-encapsulated melanoma (CheckMate 067 and CheckMate 067). J Clin Oncol 2020;38(13):1441–1451.
Disclaimer: The information provided is for educational purposes only and should not be considered a substitute for professional medical advice. Always consult a healthcare professional before starting any new medication or treatment plan.